Lenalidomide is effective as salvage therapy in refractory or relapsed multiple myeloma: analysis of the Spanish Compassionate Use Registry in advanced patients


Por: Alegre, A, Aguado, B, Giraldo, P, Rios, E, Canovas, A, Ibanez, A, Castillo, I, Hernandez, MT, Oriol, A, Palomera, L, Rodriguez, JN, Garcia, FL, Calvo, JM, Martinez-Chamorro, C, de la Serna, J and Lahuerta, JJ

Publicada: 1 mar 2011
Categoría: Hematology

Resumen:
We evaluated the clinical results of lenalidomide (Len) as a compassionate salvage therapy in refractory/relapsed multiple myeloma (MM) patients. A nationwide multi-centre, retrospective research study was performed to evaluate clinical data from patients with advanced MM for which compassionate use of lenalidomide was requested. The primary endpoints were the overall response rate (ORR) and the time to progression (TTP). Secondary objectives included safety and overall survival (OS) since starting of lenalidomide therapy. Data collected from the Spanish Compassionate Use Registry included 111 patients treated in 2006-2008. The median (range) number of previous treatment lines was 3 (1-8). The median duration of lenalidomide treatment while on study was of 4.9 months (1-18). Dexamethasone was given concomitantly with Len in 89% of patients. The ORR was 66% (4% of patients had stringent complete, 11% complete and 11% very good partial responses). Median TTP and OS were 13.0 and 17.4 months, respectively. The depth of response was significantly associated with a longer OS. Toxicity, mainly myelosuppression, was predictable and manageable with Len dose adjustments and cytokine support. Lenalidomide as salvage compassionate therapy in refractory/relapsed MM showed, in this series of heavily pre-treated patients, similar efficacy to that reported in pivotal clinical trials with acceptable tolerance.

Filiaciones:
Alegre, A:
 Hosp Univ Princesa, Dept Hematol, Madrid 28006, Spain

Aguado, B:
 Hosp Univ Princesa, Dept Hematol, Madrid 28006, Spain

Giraldo, P:
 Hosp Miguel Servet, Zaragoza, Spain

Rios, E:
 Hosp Virgen Rocio, Seville, Spain

Canovas, A:
 Hosp Cruces, Baracaldo, Spain

Ibanez, A:
 Complejo Hosp Univ Albacete, Albacete, Spain

Castillo, I:
 Hosp Gen Elda, Elda, Spain

Hernandez, MT:
 Hosp Univ Canarias, Tenerife, Spain

:
 Hosp Badalona Germans Trias & Pujol, Badalona, Spain

Palomera, L:
 Hosp Clin Univ Lozano Blesa, Zaragoza, Spain

Rodriguez, JN:
 Hosp Juan Ramon Jimenez, Huelva, Spain

Garcia, FL:
 Hosp Univ Princesa, Dept Hematol, Madrid 28006, Spain

Calvo, JM:
 Hosp Gen Lanzarote, Gran Canaria, Spain

Martinez-Chamorro, C:
 Hosp Univ Quiron, Madrid, Spain

de la Serna, J:
 Hosp Univ Doce Octubre, Madrid, Spain

Lahuerta, JJ:
 Hosp Univ Doce Octubre, Madrid, Spain
ISSN: 09255710





International Journal of Hematology
Editorial
Springer Japan, SHIROYAMA TRUST TOWER 5F, 4-3-1 TORANOMON, MINATO-KU, TOKYO, 105-6005, JAPAN, Japón
Tipo de documento: Article
Volumen: 93 Número: 3
Páginas: 351-360
WOS Id: 000288558700012
ID de PubMed: 21360065

MÉTRICAS